[Cystoid macular edema secondary to albumin-bound paclitaxel therapy for pancreatic cancer].
Nihon Shokakibyo Gakkai Zasshi
; 118(3): 272-278, 2021.
Article
em Ja
| MEDLINE
| ID: mdl-33692262
ABSTRACT
Cystoid macular edema (CME) is a rare adverse event induced by taxane-based chemotherapy. Here, we describe the case of a 71-year-old man who developed bilateral CME during treatment with nab-paclitaxel (nab-PTX) for unresectable pancreatic cancer. Two months after drug discontinuation, his vision improved, and there was significant reduction in the CME on optical coherence tomography. CME is an adverse event that can be treated with the early withdrawal of nab-PTX. Oncologists who use nab-PTX should be aware of this adverse event for timely patient referral to an ophthalmologist and appropriate treatment that would enable the preservation of the patient's visual acuity.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Edema Macular
/
Antineoplásicos Fitogênicos
Limite:
Aged
/
Humans
/
Male
Idioma:
Ja
Ano de publicação:
2021
Tipo de documento:
Article